Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CYCN

CYCN - Cyclerion Therapeutics Inc Stock Price, Fair Value and News

$1.43-0.07 (-4.67%)
Market Closed

64/100

CYCN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

64/100

CYCN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.93

Target 3M

$1.63

Target 6M

$1.72

CYCN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYCN Price Action

Last 7 days

5.9%

Last 30 days

19.2%

Last 90 days

-25.5%

Trailing 12 Months

-41.6%

CYCN RSI Chart

CYCN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYCN Valuation

Market Cap

5.6M

Price/Earnings (Trailing)

-2.55

Price/Sales (Trailing)

2.1

Price/Free Cashflow

-4.08

CYCN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.93

Target 3M

$1.63

Target 6M

$1.72

CYCN Fundamentals

CYCN Revenue

Revenue (TTM)

2.9M

Rev. Growth (Yr)

351.03%

Rev. Growth (Qtr)

840.86%

CYCN Earnings

Earnings (TTM)

-2.2M

Earnings Growth (Yr)

-34.99%

Earnings Growth (Qtr)

-201.23%

CYCN Profitability

Return on Equity

-23.06%

Return on Assets

-21.11%

Free Cashflow Yield

-24.5%

CYCN Investor Care

Shares Dilution (1Y)

44.84%

Diluted EPS (TTM)

-0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024001.6M2.0M
202300722.8K1.1M
20224.6M1.9M1.6M297.0K
20212.7M3.1M3.5M3.9M
20204.0M3.4M2.8M2.3M
20190004.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cyclerion Therapeutics Inc

CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEcyclerion.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Cyclerion Therapeutics Inc Frequently Asked Questions

CYCN is the stock ticker symbol of Cyclerion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Cyclerion Therapeutics Inc is 5.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CYCN's fair value in chart for subscribers.

The fair value guage provides a quick view whether CYCN is over valued or under valued. Whether Cyclerion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cyclerion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCN.

As of Wed Jan 28 2026, CYCN's PE ratio (Price to Earnings) is -2.55 and Price to Sales (PS) ratio is 2.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCN PE ratio will change depending on the future growth rate expectations of investors.